MG-132isapotent,non-specific20Sproteasomeinhibitor,withIC₅₀of24.2nMfortheβ5chymotrypsin-likeactivesite.

IC50:24.2nM(chymotrypsin-likeactivity)^[1]

Dose-dependentinhibitionofcellgrowthisobservedinHeLacellswithanIC₅₀ofapproximately5μMMG132for24h.MG132inhibitsthegrowthofHeLacellsviainducingthecellcyclearrestaswellastriggeringapoptosis^[2].MG-132inhibitsC6gliomacellproliferationinatime-anddose-dependentmanner(theIC₅₀valueat24his18.5μM).MG-132(18.5μM)suppressestheproteasomeactivitybyabout70%at3h.MG-132inducesapoptosisviadown-regulationofantiapoptoticproteinsBcl-2andXIAP,up-regulationofpro-apoptoticproteinBaxandcaspase-3,andproductionofcleavedC-terminal85kDaPARP.MG-132alsocausesamorethan5-foldincreaseofreactiveoxygenspecies^[3].TheIC₅₀ofMG-132againstHeLa,CaSki,andC33AcervicalcancercellsviABIlityafter48hofincubationis2.1,3.2,and5.2μM,respectively^[4].

TheinvivoantitumoractivityofMG-132againstcervicalcancerisexaminedusings.c.xenograftmodels.MG-132isinjectedat1mg/kgusingthefollowingschedule:days1,4,8,12,1518,23,and26formicebearingHeLatumors.ThegrowthinhibitionratesofMG132comparedtocontrolis49%^[4].MG-132(i.p.,0.1mg/kg/day)attenuatespressure-overload-inducedcardiachypertrophyandimprovescardiacfunctioninaBDominalaorticbanding(AAB)ratsthroughregulationofERK1/2andJNK1signalingpathways^[5].

• [1].BraunHA,etal.Tripeptidemimeticsinhibitthe20Sproteasomebycovalentbondingtotheactivethreonines.JBiolChem.2005Aug5;280(31):28394-401.

  [2].HanYH,etal.TheeffectofMG132,aproteasomeinhibitoronHeLacellsinrelationtocellgrowth,reactiveoxygenspeciesandGSH.OncolRep.2009Jul;22(1):215-21.

  [3].FanWH,etal.ProteasomeinhibitorMG-132inducesC6gliomacellapoptosisviaoxidativestress.ActaPharmacolSin.2011May;32(5):619-25.

  [4].MatsumotoY,etal.EnhancedefficacyagainstcervicalcarcinomasthroughpolymericmicellesphysicallyincorporatingtheproteasomeinhibitorMG132.CancerSci.2016Jun;107(6):773-81.

  [5].ChenB,etal.MG132,aproteasomeinhibitor,attenuatespressure-overload-inducedcardiachypertrophyinratsbymodulationofmitogen-activatedproteinkinasesignals.ActaBiochimBiophysSin(Shanghai).2010Apr;42(4):253-8.

Aftergrowingonsix-wellplates(3×10⁵cells/well)for24h,C6gliomacellsaretreatedwitheitherPBS(control)or18.5μMMG-132for3,6,12,or24hat37°C.CellsarethoroughlyscrapedfromtheculturedisheswithacellscraperandwashedwithcoldPBS.Aftercentrifugationfor10minat800×g,thecellpelletsaresUSPendedinice-coldbuffer(50mMTris-HCl,pH7.5,20μMATP,5mMMgCl₂,1mMdithiothreitol,and20%glycerol)andhomogenizedwithaPyrexglassmicrohomogenizer(20strokes).Thehomogenateiscentrifugedat15000×gfor10minat4°Ctoobtainsupernatant.Proteinconcentrationisdeterminedusingproteinassaykits.Atotalof10μL(1μg/μL)ofeachfreshlymadesupernatantisincubatedina96-wellplateat37°Cfor30minwith10μLof300μMofSuccinyl-LLVY-AMCand85μLofassaybuffer(20mMTris-HCl,pH7.5,and20%glycerol).ReleaseoffluorescentAMCismeasuredwithaspectrofluorometerat440nmwithanexcitationwavelengthof380nm^[3].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

MG-132isdissolvedinPBStoastorageconcentrationof50μM^[3].

C6gliomacellsareseededonto96-wellmicroplates(3×10⁴cells/well)andculturedfor24h.ThecellsaretreatedwithPBSorMG-132finalconcentrationsof10,20,30,and40μM,respectively.CellviabilityisassessedusinganMTTassayat3,6,12,and24hafterMG-132treatment.Theabsorbancevalueat570nmisreadusinganautomaticmulti-wellspectrophotometer.C6gliomacells(3×10⁵cells/well)areallowedtogrowoncoverslipsin6-wellcultureplatesfor24h.ThecellsarethentreatedwitheitherPBS(control)or18.5μMMG-132at37°Cfor24h.Cellsgrowingonglasscoverslipsarefixedinmethanolfor5minatroomtemperature.ThefixedcellsarewashedtwicewithPBSandthenincubatedwithHoechst33342for5minatroomtemperatureandobservedunderafluorescencemicroscope.Fragmentedorcondensednucleiarescoredasapoptotic^[3].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

MG-132isdissolvedinvehicle(saline)(Mice)^[4].
MG-132isdissolvedinvehicle(0.1%DMSO)(Rat)^[5].

Mice^[4]
C.B-17/lcr-scid/scidJclmiceareinoculateds.c.withHeLa,CaSki,orC33A(1×10⁷cells).Tumorsareallowedtogrowfor1week.Micearekilledandtumorsareremoved.Tumorsarethencutinto2-mmdiameterpiecesands.c.transplantedinC.B-17/lcr-scid/scidJclmice(n=6pergroup).Oneweekafterinoculation,micearetreatedwithi.v.injectionofsaline(control),MG-132(1mg/kg/dose)twiceaweekfor4weeks.Thevolume(V)oftumorsismeasuredbeforeeveryinjection,asestimatedusingequationV=a×b²/2whereaandbaremajorandminoraxesofthetumormeasuredbyacaliper,respectively.
Rat^[5]
MaleSprague-Dawleyrats(8weeksold,180-230g)areusedtoestablishpressure-overloadmodel.Allanimalsareseparatedintofourgroups(10ratspergroup):(i)vehicle-treatedshamgroup;(ii)MG-132-treatedshamgroup;(iii)vehicle-treatedabdominalaorticbanding(AAB)group;and(iv)MG-132-treatedAABgroup.Underintraperitonealpentobarbital(50mg/kg)anesthesia,AABiscreatedusinga5-0suturetiedtwicearoundtheabdominalaortainwhicha21-gaugeneedleisinserted.Theneedleisthenretractedyieldinga70-80%constrictionwithanouteraorticdiameterof~0.8mm.Intheshamsurgeryrats,thesamesurgeryisperformedexcepttheaortaisconstricted.AtDay3afterthesurgery,MG-132-treatedratsareintraperitoneallyinjectedwith0.1mg/kg/dayofMG-132for8weeks.Allcontrolanimalsareinjectedwithacorrespondingvolumeofvehicleonly(0.1%DMSO).MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

• [1].BraunHA,etal.Tripeptidemimeticsinhibitthe20Sproteasomebycovalentbondingtotheactivethreonines.JBiolChem.2005Aug5;280(31):28394-401.

  [2].HanYH,etal.TheeffectofMG132,aproteasomeinhibitoronHeLacellsinrelationtocellgrowth,reactiveoxygenspeciesandGSH.OncolRep.2009Jul;22(1):215-21.

  [3].FanWH,etal.ProteasomeinhibitorMG-132inducesC6gliomacellapoptosisviaoxidativestress.ActaPharmacolSin.2011May;32(5):619-25.

  [4].MatsumotoY,etal.EnhancedefficacyagainstcervicalcarcinomasthroughpolymericmicellesphysicallyincorporatingtheproteasomeinhibitorMG132.CancerSci.2016Jun;107(6):773-81.

  [5].ChenB,etal.MG132,aproteasomeinhibitor,attenuatespressure-overload-inducedcardiachypertrophyinratsbymodulationofmitogen-activatedproteinkinasesignals.ActaBiochimBiophysSin(Shanghai).2010Apr;42(4):253-8.

475.62

C₂₆H₄₁N₃O₅

133407-82-6

4°C,protectfromlight

RoomtemperatureincontinentalUS;mayvaryelsewhere

10mMinDMSO

*"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">

Purity:>98.0%

SelectBatch:HY-13259-21783

DataSheet(123KB)SDS(120KB)

COA(92KB)HNMR(234KB)

HandlingInstructions(1252KB)

• [1].BraunHA,etal.Tripeptidemimeticsinhibitthe20Sproteasomebycovalentbondingtotheactivethreonines.JBiolChem.2005Aug5;280(31):28394-401.

  [2].HanYH,etal.TheeffectofMG132,aproteasomeinhibitoronHeLacellsinrelationtocellgrowth,reactiveoxygenspeciesandGSH.OncolRep.2009Jul;22(1):215-21.

  [3].FanWH,etal.ProteasomeinhibitorMG-132inducesC6gliomacellapoptosisviaoxidativestress.ActaPharmacolSin.2011May;32(5):619-25.

  [4].MatsumotoY,etal.EnhancedefficacyagainstcervicalcarcinomasthroughpolymericmicellesphysicallyincorporatingtheproteasomeinhibitorMG132.CancerSci.2016Jun;107(6):773-81.

  [5].ChenB,etal.MG132,aproteasomeinhibitor,attenuatespressure-overload-inducedcardiachypertrophyinratsbymodulationofmitogen-activatedproteinkinasesignals.ActaBiochimBiophysSin(Shanghai).2010Apr;42(4):253-8.

品牌介绍

托烷司琼临床评价药物相关作用适应症托烷司琼CAS号:89565-68-4英文名称:Tropisetron英文同义词:icf205-930;TROPICACID;TROPISETRON;SS-TROPISETRON;BETA-TROPISETRON;Tropisetron(ICS205930);TROPISHTRONHYDROCHLORIDE;Indole-3-carbonylchloride;3-Tropanylindole-3-carboxylate;lαH，5Αh-Tropan-3α-ylindole-3-carboxylate中文名称:托烷司琼中文同义词:托普西隆;托普西龙;曲匹西龙;托烷司琼;Β-托烷司琼;CS-348;Β-内托烷司琼;吲哚-3-甲酰氯;Β-托烷司琼(光学异构体);Β-托烷司琼,托烷司琼异构体CBNumber:CB3236404分子式:C17H20N2O2分子量:284.35MOLFile:89565-68-4.mol化学性质安全信息用途供应商112化学性质安全信息用途供应商112托烷司琼化学性质熔点:201-202°C沸点:448.5±35.0°C(Predicted)密度:1.26储存条件:2-8°C溶解度:H2O:soluble形态:solid酸度系数(pKa):15.38±0.30(Predicted)颜色:whiteCAS数据库:Chemicalbook89565-68-4(CASDataBaseReference)安全信息WGKGermany:3托烷司琼化学药品说明书托烷司琼|药物应用信息托烷司琼性质、用途与生产工艺临床评价Sorbe等报道本品对含顺铂(剂量50～89mg/m2)化疗方案引起的急性呕吐完全控制率为63%。58例恶性肿瘤化疗所致恶心、呕吐者，应用托烷司琼或昂丹司琼8mg分别在同一病人前后2个化疗周期的第1d给药前30min静脉注射，并用地塞米松10mg静脉滴注。结果两药控制急性及迟发性恶心、呕吐的疗效基本相似，均可达81%～100%。本品对强致吐化疗药物顺铂的止吐疗效突出。药物相关作用饮食可略为延长本品的吸收。本品与利福平、苯巴比妥等肝酶诱导药同时使用，可加快代谢，故快代谢型者需增加剂量，慢者则不必。西咪替丁等肝酶抑制药对本品血药浓度无明显影响。适应症托烷司琼临床用于预防和治疗癌症化疗引起的恶心和呕吐。化学性质结晶，熔点201-202℃(二氯甲烷-乙酸乙酯)。单盐酸托烷司琼(TropisetronMonohydroehloride)：C17H20N2O2?HCI。[105826-92-4]。熔点283-285℃(分解)。用途有高效性和选择性的5-HT3受体拮抗剂。用于化疗所致的呕吐。用途为5-羟色胺拮抗药生产方法托品醇(I)和酰氯(Ⅱ)反应，可得托烷司琼。托烷司琼上下游产品信息上游原料托品醇下游产品

公司介绍

托烷司琼临床评价药物相关作用适应症托烷司琼CAS号:89565-68-4英文名称:Tropisetron英文同义词:icf205-930;TROPICACID;TROPISETRON;SS-TROPISETRON;BETA-TROPISETRON;Tropisetron(ICS205930);TROPISHTRONHYDROCHLORIDE;Indole-3-carbonylchloride;3-

品牌分类

黄酮类化合物 抑制性抗体 苯丙素类 酸和醛 醌类 肽 其他 酚类 萜类和糖苷类

类固醇 生物碱 糖类和糖苷类 染料试剂 生化分析试剂

显示分类

联络我们

服务热线：4000-520-616

（限工作日9:00-18:00）

QQ ：1570468124

手机：18915418616

官网：http://www.medchemexpress.com/

快速导航：

公司介绍

产品中心

新闻动态

在线咨询

联系我们

公司介绍

产品中心

新闻动态

在线咨询

联系我们

总部地址：

江苏省苏州市工业园区星湖街218号 苏州生物医药产业园一期（生物纳米园）A4-216(邮编：215125)

工作时间：周一至周五9:00~18:00

技术支持：

Email：info@ebiomall.com

短信：18915418616

服务热线：

4000-520-616（全国）

☏  0512-67156496（苏州）

版权信息：

©  2015-2022 苏州蚂蚁淘生物科技有限公司 版权所有 中国

网站备案：

苏ICP备17049038号-1

苏公网安备 32059002001627号

友情链接：

联系QQ:764052152

medix官网 medkoo采购 megazyme正品 microspheres代购 midlandsci报价 minerva清关 molecular molinnov moltox mpbio Reagentproteins产品 Polysciences说明书 electronmicroscopysc Viskase api-services产品代理 美国Lucigen imgenexindia代理 蚂蚁淘 广东体必康生物科技有限公司

免责声明：

本站有部分内容来自互联网，如无意中侵犯了某个媒体 、公司 、企业或个人等的知识产权，请来电或致函告之，
本网站将在规定时间内给予删除等相关处理。

扫描二维码关注官方微信

获取最新促销及产品信息